The aim of this study was to investigate whether L1CAM can predict lymph node metastasis and could therefore be used preoperatively to identify patients with low to high-intermediate risk endometrial cancer who would profit from a lymphadenectomy and an adjuvant treatment. The gene discussed is L1CAM; the disease is metastatic malignant neoplasm in the lymph nodes.